A higher-than-expected prevalence of monocytosis was seen in patients with polycythemia vera (PV) in a study involving 267 individuals. Moreover, mutation profile and age distribution in monocytosis patients appeared to be similar to what is seen in those with chronic myelomonocytic leukemia.
Investigators looked at the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in PV. Among the results:
- 2 in every 10 patients displayed an absolute monocyte count of ≥1 × 109/L.
- This count was ≥1.5 × 109/L in 7%.
- In univariate analysis, patients with AMC ≥1.5 × 109/L were more likely to experience worse overall and myelofibrosis-free survival (MFFS).
- The overall survival significance held up during multivariable analysis, whereas MFFS did not.
- Other independent risk factors for overall survival included unfavorable karyotype, older age, and leukocytosis ≥15 × 109/L.
Barraco D, Cerquizzi S, Gangat N, et al. Monocytosis in polycythemia vera: Clinical and molecular correlates. [Published online ahead of print May 26, 2017]. Am J Hematol. doi:10.1002/ajh.24740.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al